Clinical trials
First-line Treatment clinical trials
Below are recruiting first-line treatment clinical trials, each written for real people, not researchers. We’re tracking 408 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07408505Recruiting
New appetite drug for weight loss in advanced pancreatic cancer
This trial tests a new form of a drug (nano-megestrol acetate) to help people with advanced pancreatic cancer who are losing weight and have poor appetite. It aims to see if it can improve cachexia, a condition of severe weight loss and muscle wasting.
JinanAges 18–75 - NCT07169552RecruitingPhase 2
HC010 for first-line PD-L1 positive advanced lung cancer
This trial tests a new drug called HC010 as a first treatment for people with advanced non-small cell lung cancer that is PD-L1 positive. It aims to see if the drug can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07110038RecruitingPhase 2
Study of Enfortumab Vedotin Plus Avelumab for Advanced Penile Cancer
This trial tests a combination of two drugs (enfortumab vedotin and avelumab) as a first treatment for men with advanced or metastatic penile cancer that cannot be removed by surgery. The goal is to see if this new combination can shrink tumors and improve outcomes.
DresdenAges 18 years+ - NCT07285889RecruitingPhase 1/Phase 2
Jaktinib as first treatment for acute graft-versus-host disease
This trial tests a new pill called jaktinib for people who develop moderate to severe acute graft-versus-host disease (aGVHD) after a stem cell transplant. The goal is to see if adding jaktinib to standard steroid therapy can better control the disease.
Hangzhou, ZhejiangAges 18 years+ - NCT07518173RecruitingPhase 3
BL-M07D1 plus Pertuzumab for HER2-positive breast cancer
This trial tests whether a new cancer drug called BL-M07D1, combined with pertuzumab, works better or as well as standard chemotherapy for advanced HER2-positive breast cancer that has spread or come back. HER2-positive means the cancer cells have high levels of a protein called HER2, which makes them grow faster.
Guangzhou, GuangdongAges 18–75 - NCT07490301RecruitingPhase 2/Phase 3
Study of a new drug combo for first-line metastatic pancreatic cancer
This trial tests a new targeted drug, telisotuzumab adizutecan, combined with standard chemotherapy (FOLFOX) for people with advanced pancreatic cancer that has spread. The goal is to see if this combination works better than current treatments.
Chicago, IllinoisAges 18 years+ - NCT07487896RecruitingPhase 3
YL201 vs. chemo for advanced esophageal cancer after first treatment
This trial tests a new drug called YL201 against standard chemotherapy for people with advanced esophageal squamous cell carcinoma that has gotten worse after one prior treatment. The goal is to see if YL201 works better at controlling the cancer.
Anqing, AnhuiAges 18 years+ - NCT07479797RecruitingPhase 3
Comparing two CAR T-cell therapies for large B-cell lymphoma after first treatment
This trial tests a new CAR T-cell therapy, KITE-753, against an approved one, Yescarta (axicabtagene ciloleucel), for people with large B-cell lymphoma that came back or didn't respond to first-line treatment. The goal is to see which works better.
Goodyear, ArizonaAges 18 years+ - NCT06832267Recruiting
RMTT chemo for newly diagnosed PCNS lymphoma
This trial tests a combination of four chemotherapy drugs (Rituximab, Methotrexate, Temozolomide, and Thiotepa) as the first treatment for people newly diagnosed with primary central nervous system diffuse large B-cell lymphoma. It aims to see if this regimen is safe and effective for patients who have not had any prior systemic therapy.
Hangzhou, ZhejiangAges 18–75 - NCT07340723RecruitingPhase 2
New treatment study for grade II acute GVHD after transplant
This study tests a new first-line therapy for patients who develop grade II acute graft-versus-host disease (GVHD) after their first stem cell transplant. It aims to find better ways to treat this complication.
Beijing, Beijing MunicipalityAges 14 years+ - NCT07247227Recruiting
Sugemalimab plus chemotherapy for advanced lung cancer
This trial tests a new immunotherapy drug (sugemalimab) combined with chemotherapy as a first treatment for advanced non-small cell lung cancer. It aims to see if this combination works well in real-world patients.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06754059Recruiting
Pyrotinib with trastuzumab for HER2-positive breast cancer maintenance
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) as maintenance therapy to keep HER2-positive breast cancer that has spread under control. It is for women who have already received some first-line treatment and are stable enough to continue therapy.
Fuzhou, FujianAges 18–70 - NCT07190677Recruiting
Nivolumab plus ipilimumab with chemo for advanced lung cancer
This trial tests combining two immunotherapy drugs (nivolumab and ipilimumab) with chemotherapy as a first treatment for advanced lung cancer that has spread or come back. It may help if your cancer hasn't been treated before and doesn't have certain genetic changes.
Pavia, LombardyAges Any age - NCT06434480Recruiting
SBRT for liver cancer with limited growth on first immunotherapy
This trial tests whether a targeted radiation therapy (SBRT) can help people with liver cancer whose disease has only a few new spots growing while on first-line immunotherapy. It aims to see if zapping those spots can control the cancer and delay the need for stronger treatments.
Hong KongAges 18 years+ - NCT07008235RecruitingPhase 2/Phase 3
Testing two drugs for upset stomach relief
This trial tests whether a combination of two medications, amitriptyline and trifluoperazine, can help patients with ongoing discomfort in the upper stomach (functional dyspepsia). It may be an option if other treatments haven't worked.
DhakaAges 18–60 - NCT07002346RecruitingPhase 3
Immunotherapy and bevacizumab for advanced ovarian clear cell cancer
This trial tests a combination of an immunotherapy drug (QL1706) and a targeted therapy (bevacizumab) for women with newly diagnosed advanced ovarian clear cell carcinoma. The goal is to see if this combination works better than standard treatment after surgery.
Wuhan, HubeiAges 18–75 - NCT06951503RecruitingPhase 3
AK112 plus chemo for first-line metastatic colorectal cancer
This trial tests a new drug called AK112 combined with chemotherapy as a first treatment for people with metastatic colorectal cancer. The goal is to see if the combination helps shrink tumors and improve survival better than chemotherapy alone.
Guanzhou, GuangdongAges 18–75 - NCT06738160RecruitingPhase 2
Combination therapy for advanced lung cancer with bone metastases
This trial tests a new combination of drugs and radiation to improve the effects of first-line chemotherapy and immunotherapy for patients with advanced non-small cell lung cancer that has spread to the bones. The goal is to help shrink tumors and potentially improve overall outcomes.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06727981Recruiting
Immunotherapy as first treatment for stomach cancer
This trial tests immunotherapy as the first treatment for people with advanced or locally advanced stomach cancer. It may help if you haven't had any prior anti-cancer therapy and are starting treatment soon.
Jinan, ShandongAges 18–100 - NCT07778316RecruitingPhase 3
Tarlatamab for small cell lung cancer after first chemotherapy
This trial tests a new drug called tarlatamab, given either as an injection under the skin or through an IV, for people with extensive-stage small cell lung cancer that has grown or come back after one round of chemotherapy. The goal is to see which way of giving the drug works better and is safer.
Orlando, FloridaAges 18–99 - NCT07679061Recruiting
Nivolumab plus ipilimumab for liver cancer
This trial tests a combination of two immunotherapy drugs, nivolumab and ipilimumab, as a first treatment for liver cancer that cannot be removed by surgery or has come back after local treatments.
Minato-ku, TokyoAges 18 years+ - NCT07670273RecruitingPhase 2
Drug combo for advanced HER2 bile duct cancer
This trial tests a combination of three drugs (trastuzumab rezetecan, adebrelimab, and lenvatinib) as a first treatment for people with advanced HER2-positive or HER2-low bile duct or gallbladder cancer. The goal is to see if this combination helps shrink or control the cancer.
BeijingAges 18–75 - NCT07669519RecruitingPhase 3
Supplement for fatigue in stage IV colon cancer
This study tests an oral supplement (Nuvastatic) to see if it helps reduce fatigue in people with stage IV colon cancer who are starting chemotherapy for the first time. If you are 18–65 and have fatigue that is affecting you, this trial might offer a way to feel better.
Srikakulam, Andhra PradeshAges 18–65 - NCT07666555RecruitingPhase 2
Culmerciclib rechallenge for HR+ HER2- breast cancer
This trial tests a new drug called Culmerciclib for women with advanced HR-positive, HER2-negative breast cancer that has stopped responding to a CDK4/6 inhibitor with hormone therapy. The goal is to see if giving this drug again can help when other treatments no longer work.
ShanghaiAges 18–75
Hear when a new First-line Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for first-line treatment?
- Yes. Clin2 currently lists 408 recruiting first-line treatment studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a first-line treatment trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a first-line treatment trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.